# Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

> **NCT01426009** · PHASE2 · COMPLETED · sponsor: **Sunovion Respiratory Development Inc.** · enrollment: 140 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** EP-101 via nebulizer (eFlow®) 25 ug
- **DRUG:** EP-101 via nebulizer (eFlow®) 50 ug
- **DRUG:** EP-101 via nebulizer (eFlow®) 100 ug
- **DRUG:** Placebo EP-101
- **DRUG:** Tiotropium bromide via (Spiriva® Handihaler®)
- **DRUG:** Ipratropium bromide Inhalation Solution via Handihaler® DPI
- **DRUG:** EP-101 via nebulizer (eFlow®) 200 ug

## Key facts

- **NCT ID:** NCT01426009
- **Lead sponsor:** Sunovion Respiratory Development Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2018-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01426009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01426009, "Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01426009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*